Posted by Michael Wonder on 15 Nov 2018
Modis Therapeutics announces PRIME designation granted by the EMA to MT1621 for the treatment of TK2 deficiency
13 November 2018 - Modis Therapeutics announced today that the EMA has granted PRIME (PRIority MEdicines) designation to MT1621, Modis’ investigational treatment for patients with thymidine kinase 2 deficiency.
MT1621 has also been granted orphan drug designation by both the FDA and EMA.
